Senseonics Reports Quarterly Earnings, Falls Short of Expectations

Senseonics (NYSE:SENS) released its quarterly earnings on Monday. The company reported an earnings per share (EPS) of ($0.12) for the quarter, which was below analysts' expectations that anticipated an EPS of ($0.03). This represents a miss of ($0.09).

Additionally, Senseonics recorded a negative net margin of 362.30% and a substantial negative return on equity of 842.25%. Given these results, the company has adjusted its guidance for the fiscal year 2025.

Senseonics Stock Performance

On Monday, the stock of Senseonics increased by 2.4%, trading at $0.87 during midday. A total of 12,448,094 shares were exchanged, slightly lower than the average volume of 14,901,513. Currently, Senseonics has a market capitalization of approximately $517.93 million and a negative price-to-earnings (P/E) ratio of -6.69, with a beta of 0.69. The company holds a debt-to-equity ratio of 59.17, reflecting its financial leverage, and a current ratio of 2.47, indicating its short-term financial health. The quick ratio stands at 2.38. Over the past year, the stock has fluctuated, with a low of $0.25 and a high of $1.40. The 50-day moving average for the stock is $0.84, while the 200-day moving average is $0.53.

Analyst Opinions and Ratings

Several analysts have recently shared their views on Senseonics. StockNews.com began their coverage of the stock with a "sell" rating. In contrast, HC Wainwright reiterated a "buy" rating for the shares and set a price target of $2.00.

Insider Activity

In recent insider transactions, CEO Timothy T. Goodnow acquired 315,000 shares of the company's stock on December 10th, purchasing them at an average price of $0.31 per share. This transaction was valued at $97,650.00, and after this purchase, his total holdings in the company increased to 11,310,355 shares, worth about $3,506,210.05. Likewise, CFO Frederick T. Sullivan acquired 124,933 shares on December 12th at an average price of $0.38 per share, totaling approximately $47,474.54. Following this transaction, he now holds 2,478,844 shares valued at about $941,960.72. Company insiders collectively own 3.60% of the stock.

About Senseonics

Senseonics Holdings, Inc. is a medical technology company that specializes in the development and manufacturing of continuous glucose monitoring (CGM) systems aimed at helping people with diabetes in the U.S. and beyond. Its product line includes Eversense, Eversense XL, and Eversense E3, which are implantable CGM systems that measure glucose levels through an under-the-skin sensor, along with a removable and rechargeable smart transmitter and a user-friendly app for effective diabetes management.

Earnings, Stocks, Investment